Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Psychosis Overview | 8 | 1 |
| Therapeutics Development | 9 | 1 |
| Pipeline Products for Psychosis Overview | 9 | 1 |
| Psychosis Therapeutics under Development by Companies | 10 | 1 |
| Psychosis Pipeline Products Glance | 11 | 2 |
| Clinical Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Psychosis Products under Development by Companies | 13 | 1 |
| Psychosis Companies Involved in Therapeutics Development | 14 | 12 |
| Acadia Pharmaceuticals Inc. | 14 | 1 |
| Addex Therapeutics Ltd | 15 | 1 |
| Evotec AG | 16 | 1 |
| Gabather AB | 17 | 1 |
| Glenmark Pharmaceuticals Ltd. | 18 | 1 |
| Heptares Therapeutics Limited | 19 | 1 |
| Integrative Research Laboratories Sweden AB | 20 | 1 |
| Merck &Co., Inc. | 21 | 1 |
| Newron Pharmaceuticals S.p.A. | 22 | 1 |
| Reviva Pharmaceuticals Inc. | 23 | 1 |
| Sumitomo Dainippon Pharma Co., Ltd. | 24 | 1 |
| Sunovion Pharmaceuticals Inc. | 25 | 1 |
| Psychosis Therapeutics Assessment | 26 | 7 |
| Assessment by Monotherapy Products | 26 | 1 |
| Assessment by Target | 27 | 2 |
| Assessment by Mechanism of Action | 29 | 2 |
| Assessment by Route of Administration | 31 | 1 |
| Assessment by Molecule Type | 32 | 1 |
| Drug Profiles | 33 | 27 |
| ADX-88178 Drug Profile | 33 | 2 |
| CB-0306 Drug Profile | 35 | 1 |
| Drug to Agonize Muscarinic M4 Receptors for Psychiatric Diseases and Alzheimer's Disease Drug Profile | 36 | 1 |
| evenamide Drug Profile | 37 | 3 |
| GT-001 Drug Profile | 40 | 1 |
| GT-002 Drug Profile | 41 | 1 |
| GT-004 Drug Profile | 42 | 1 |
| GT-006 Drug Profile | 43 | 1 |
| HUF-101 Drug Profile | 44 | 1 |
| IRL-790 Drug Profile | 45 | 1 |
| pimavanserin tartrate Drug Profile | 46 | 5 |
| RP-5063 Drug Profile | 51 | 2 |
| SEP-39 Drug Profile | 53 | 1 |
| Small Molecule for Psychosis Drug Profile | 54 | 1 |
| Small Molecule to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases Drug Profile | 55 | 1 |
| Small Molecule to Modulate Metabotropic Glutamate Receptor 2 for Psychosis Drug Profile | 56 | 1 |
| Small Molecules to Agonize M1/M4 Muscarinic Acetylcholine Receptors for Psychosis Drug Profile | 57 | 1 |
| Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis Drug Profile | 58 | 1 |
| Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis Drug Profile | 59 | 1 |
| Psychosis Dormant Projects | 60 | 1 |
| Psychosis Discontinued Products | 61 | 1 |
| Psychosis Product Development Milestones | 62 | 7 |
| Featured News &Press Releases | 62 | 1 |
| May 31, 2016: ACADIA Pharmaceuticals Announces NUPLAZID (pimavanserin) Is Now Available for the Treatment of Hallucinations and Delusions Associated with Parkinson s Disease Psychosis | 62 | 1 |
| Apr 29, 2016: FDA approves first drug to treat hallucinations and delusions associated with Parkinson s disease | 62 | 1 |
| Mar 29, 2016: FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals NUPLAZID(Pimavanserin) for the Treatment of Psychosis Associated with Parkinson s Disease Outweigh the Risks | 63 | 1 |
| Jan 29, 2016: ACADIA Pharmaceuticals Announces FDA Advisory Committee Meeting to Review NUPLAZID(Pimavanserin) for the Treatment of Parkinson s Disease Psychosis | 64 | 1 |
| Nov 17, 2014: Heptares First-In-Class Selective Muscarinic Agonists Chosen As One Of Top Neuroscience Projects To Watch | 64 | 1 |
| Sep 02, 2014: Acadia Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID (Pimavanserin) for Parkinson s Disease Psychosis | 65 | 1 |
| Aug 28, 2014: ACADIA Pharmaceuticals Announces Trade Name NUPLAZID for Pimavanserin | 65 | 1 |
| Apr 14, 2010: Joseph Friedman To Present Data From ACADIA's First Phase III Trial With Pimavanserin For PDP At 62nd American Academy Of Neurology Annual Meeting | 66 | 1 |
| Sep 01, 2009: ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis | 67 | 1 |
| May 06, 2009: ACADIA Pharmaceuticals and Biovail Announce Completion of Enrollment in First Pivotal Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis | 67 | 1 |
| Jun 11, 2007: ACADIA Pharmaceuticals Initiates Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis | 68 | 1 |
| Appendix | 69 | 2 |
| Methodology | 69 | 1 |
| Coverage | 69 | 1 |
| Secondary Research | 69 | 1 |
| Primary Research | 69 | 1 |
| Expert Panel Validation | 69 | 1 |
| Contact Us | 69 | 1 |
| Disclaimer | 70 | 1 |